Endometrial Serous Adenocarcinoma Clinical Trials

37 clinical trials for Endometrial Serous Adenocarcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma — RECRUITING · PHASE3
• Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers — RECRUITING
• Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer — RECRUITING · PHASE3
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone — ACTIVE_NOT_RECRUITING · PHASE2
• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy — ACTIVE_NOT_RECRUITING · PHASE1
• PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer — ACTIVE_NOT_RECRUITING · NA
• Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer — TERMINATED · PHASE2
• Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer — COMPLETED · PHASE2
• Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer — COMPLETED
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers — COMPLETED · PHASE1
• Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol — COMPLETED · PHASE3
• AMT-151 in Patients With Selected Advanced Solid Tumours — OTHER · PHASE1
• Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer — TERMINATED · PHASE2
• Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer — COMPLETED · PHASE2
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer — COMPLETED · PHASE2
• Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery — COMPLETED
• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer — OTHER · PHASE3
• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer — OTHER · PHASE2
• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE1
• Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer — COMPLETED · PHASE2
• Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer — WITHDRAWN · PHASE2
• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer — OTHER · PHASE3
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer — COMPLETED · PHASE2
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer — COMPLETED · PHASE1
• Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer — COMPLETED · PHASE2
• Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer — COMPLETED · PHASE2
• Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer — COMPLETED · PHASE1
• Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer — COMPLETED · PHASE3
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer — COMPLETED · PHASE1
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer — COMPLETED · PHASE1

Refine this search